The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation hones in on what the audience can expect and look forward to learn more about in the coming months.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation discusses the growing trend of patient involvement, the factors for and benefits of NIT development, lessons from artificial intelligence and more.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation focuses largely on the various challenges associate with adopting and communicating new nomenclature for liver disease.
This episode From the Vault looks back at the first episode dedicated entirely to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to explore the psychology of decision-making around diet and professional support.
On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation From the Vault to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation focuses on the increasing importance of omics and potentially powerful weight-loss therapies presented at the ADA meeting. Other major themes in this session include insights on the role of artificial intelligence and epigenetics.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This final session focuses on another paper by Vincent Wong which sparks discussion around the plausibility of shifting from biopsy to NITs and the cost effectiveness and frequency of testing.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.
